From a therapeutic perspective, if weight loss remains the cornerstone of NAFLD patient management, sodium–glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging NAFLD therapeutic pharmacological molecules due to their ability to inhibit SREBP-1, hepatocyte inflammation, and liver fibrosis [43]. This evidence concerns the gene SREBF1 and Hepatic fibrosis.